人脂肪间充质干细胞对宫颈癌细胞的趋化性

Chemotaxis of human adipose tissue derived mesenchymal stem cells to cervical cancer cells

目的:探讨人脂肪组织来源的间充质干细胞(h ATMSC)对人宫颈癌细胞的趋化性,为将hATMSC研发成为宫颈癌的靶向治疗载体提供实验依据。方法:从剖宫产产妇的皮下脂肪中分离得到hATMSC。用成骨、成脂分化培养基诱导hATMSC,分别采用碱性磷酸酶、油红染色鉴定其多向分化能力;流式细胞仪检测其表面抗原的表达情况;qRT-PCR法分析细胞中OCT-4 m RNA的表达;Transwell实验检测h ATMSC向人宫颈鳞癌细胞SiHa、MS751、C33-A、Ca Ski以及宫颈腺癌细胞Hela迁移的能力。结果:成骨、成脂诱导14 d后,细胞碱性磷酸酶、油红染色均呈阳性;表面抗原CD90、CD44、CD105、HLA-ABC呈阳性表达,而CD34、CD45和HLA-DR呈阴性表达;细胞中OCT-4 mRNA呈高表达;hATMSC表现出明显的向人宫颈癌细胞迁移的特性,其中向C33-A细胞迁移的能力最强。结论:成功分离培养出hATMSC,细胞具有多向分化潜能的干细胞特性。hATMSC对各种人宫颈癌细胞均有明显的趋化性,提示hATMSC可作为一种潜在的细胞载体用于宫颈癌的靶向治疗。

Objective： To investigate the chemotaxis of human adipose tissue derived mesenchymal stem cell（hATMSC） to human cervical cancer cells and to provide experimental basis for the development of hATMSC as a target vehicle for the treatment of cervical cancer. Methods： Primary hATMSC from subcutaneous fat of patients undergoing cesarean section was isolated. hATMSC was induced by osteogenic and adipogenic differentiation medium, and using Alkaline Phosphatase, Oil Red O staining respectively to verify the differentiative capacity. The expression of surface antigen and OCT-4 mRNA were detected by flow cytometry and qRT-PCR, respectively. The migration ability of hATMSC to cervical cancer squamous cells Si Ha, MS751, C33-A, Ca Ski and adenocarcinoma cell Hela was detected by Transwell assay. Results： Having been incubated in osteogenic and adipogenic differentiation medium for 14 days, hATMSC was positive by Alkaline Phosphatase and Oil Red O staining. The hATMSC was positive for CD90, CD44, CD105 and HLA-ABC, but negative for CD34, CD45, HLA-DR. OCT-4 mRNA was highly expressed in hATMSC. hATMSC had high motility to migrate to cervical cancer cells, and the migration to C33-A was the strongest among them. Conclusion： hATMSC was successfully isolated and cultured, with the characteristics of stem cells having multi-directional differentiation potential. hATMSC has obvious chemotaxis to different cervical cancer cells, suggesting that hATMSC might be used as a potential carrier for targeting therapy of cervical cancer.